Home > Journals > The Quarterly Journal of Nuclear Medicine and Molecular Imaging > Past Issues > The Quarterly Journal of Nuclear Medicine 1999 December;43(4) > The Quarterly Journal of Nuclear Medicine 1999 December;43(4):297-306

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints

THE QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

A Journal on Nuclear Medicine and Molecular Imaging


A Journal on Nuclear Medicine and Molecular Imaging
Affiliated to the Society of Radiopharmaceutical Sciences and to the International Research Group of Immunoscintigraphy
Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index (SciSearch), Scopus
Impact Factor 2,481


eTOC

 

  ENDOCRINOLOGY - II
Therapy
FREEfree


The Quarterly Journal of Nuclear Medicine 1999 December;43(4):297-306

Copyright © 2000 EDIZIONI MINERVA MEDICA

language: English

The role of nuclear medicine in the management of Graves’ disease

Freitas J. E.

From the Nuclear Medicine Services St. Joseph Mercy Hospital, Ann Arbor, MI, USA Internal Medicine University of Michigan Medical School, Ann Arbor, MI, USA


FULL TEXT  


131I ther­a­py is ­safe and effec­tive for ­most Graves’ dis­ease ­patients. It is ­being ­used ­more fre­quent­ly in pre­vi­ous­ly restrict­ed pop­u­la­tions ­such as chil­dren, ado­les­cents, and wom­en of child­bear­ing age. It ­affords ­prompt, con­sis­tent ­relief of hyper­thyr­oi­dism, but per­ma­nent hypo­thy­roid­ism ­ensues in ­almost all ­patients. This com­pli­ca­tion is read­i­ly diag­nosed ­with mod­ern in ­vitro ­assays and inex­pen­sive, ­life-­long replace­ment ther­a­py ren­ders the ­patient asymp­to­mat­ic and ­able to ­resume a nor­mal life­style. Recent chang­es in NRC require­ments ­have fur­ther lib­er­al­ized the use of 131I for Graves’ dis­ease in the USA, per­mit­ting ­more ­patients to be treat­ed ­with effec­tive out­pa­tient ther­a­py. The con­tro­ver­sial ­role of 131I in exac­er­ba­tion of GO has ­been fur­ther clar­i­fied and pre­ven­tive meas­ures are avail­able.

top of page

Publication History

Cite this article as

Corresponding author e-mail